Hepatitis C Virus

Making 2030 Hepatitis C elimination goal a reality

Unitaid has invested more than US$45 million since 2015 in support of projects devoted to improving access to care for hepatitis C.   

Hepatitis C virus (HCV) is an infectious, blood-borne disease that primarily affects the liver, and can lead to serious liver damage including cirrhosis and cancer if left untreated. The World Health Organization (WHO) estimates that 58 million people suffer from HCV globally – nearly twice as many people as there are living with HIV –  with an estimated 290,000 HCV-related deaths in 2019.

In support of the global goal to eliminate viral hepatitis as a public health problem by 2030, and with particular attention to more vulnerable populations, such as those living in low- and middle-income countries (LMICs), Unitaid has invested  to make essential medicines available, simplify testing and treatment, improve diagnostic tools, bring care closer to the people at-risk, and raise awareness of treatment programmes with affected communities and governments.  

How did Unitaid make a difference? Top achievements include: 

Find out more about Unitaid’s impact in HCV – read the impact story. 

Awareness raising efforts led by Unitaid grantee Coalition PLUS helped connect at-risk populations with care. This image is part of a photo exhibition documenting the efforts of that work and the people it reached. (Photo: © Coalition PLUS / Syaiful Redzuan Md Noor)

Unitaid’s Executive Board has recognised the following as specific priorities:

  • For people living with HIV, expanding access to diagnosis and treatment of co-infections

By the numbers

  • 58 million

    Estimated number of people living with HCV in 2019.

  • 15.2 million

    Estimated number of people diagnosed with HCV.

  • 9.4 million

    Estimated number of people who have received treatment for HCV.

Sign Up for Unitaid Updates

  • This field is for validation purposes and should be left unchanged.